Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 406

1.

An emerging frontier in the treatment of acute exacerbation of idiopathic pulmonary fibrosis.

Ohshimo S, Costabel U, Shime N.

Respir Investig. 2018 Mar;56(2):97-99. doi: 10.1016/j.resinv.2017.12.003. Epub 2017 Dec 27. No abstract available.

PMID:
29548662
2.

[DGP Interstitial Lung Disease Patient Questionnaire].

Kreuter M, Ochmann U, Koschel D, Behr J, Bonella F, Claussen M, Costabel U, Jungmann S, Kolb M, Nowak D, Petermann F, Pfeiffer M, Polke M, Prasse A, Schreiber J, Wälscher J, Wirtz H, Kirsten D.

Pneumologie. 2018 Feb 21. doi: 10.1055/s-0044-100207. [Epub ahead of print] German.

PMID:
29466814
3.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.

PMID:
29414827
4.

Phenotypes of organ involvement in sarcoidosis.

Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O'Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane MP, O'Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J.

Eur Respir J. 2018 Jan 25;51(1). pii: 1700991. doi: 10.1183/13993003.00991-2017. Print 2018 Jan.

PMID:
29371378
5.

German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2018 Feb;72(2):155-168. doi: 10.1055/s-0043-123035. Epub 2018 Jan 16.

6.

Serum YKL-40 in workers at an indium-tin oxide production facility - Reply.

Bonella F, Costabel U; all co-authors.

Respirology. 2018 Mar;23(3):342. doi: 10.1111/resp.13237. Epub 2017 Dec 15. No abstract available.

PMID:
29243860
7.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

8.

Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey.

Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; HP Delphi Collaborators.

Am J Respir Crit Care Med. 2017 Nov 27. doi: 10.1164/rccm.201710-1986OC. [Epub ahead of print]

PMID:
29172641
9.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

10.

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW.

Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13.

11.

Differential diagnosis of granulomatous lung disease: clues and pitfalls: Number 4 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.

Ohshimo S, Guzman J, Costabel U, Bonella F.

Eur Respir Rev. 2017 Aug 9;26(145). pii: 170012. doi: 10.1183/16000617.0012-2017. Print 2017 Sep 30. Review.

12.

Idiopathic pleuroparenchymal fibroelastosis (PPFE) - A case study of a rare entity.

Boerner EB, Costabel U, Wessendorf TE, Theegarten D, Bonella F.

Rev Port Pneumol (2006). 2017 Nov - Dec;23(6):352-355. doi: 10.1016/j.rppnen.2017.06.006. Epub 2017 Aug 3.

13.

[Expert Knowledge and Supporting Advice for the Clinical Use of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis].

Behr J, Günther A, Kreuter M, Koschel D, Prasse A, Pfeifer M, Costabel U.

Pneumologie. 2017 Sep;71(9):567-579. doi: 10.1055/s-0043-109856. Epub 2017 Aug 3. German.

PMID:
28772332
14.

[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017].

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2017 Jul;71(7):474. doi: 10.1055/s-0043-115504. Epub 2017 Jul 5. German. No abstract available.

PMID:
28679139
15.

Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.

Bonella F, Long X, He X, Ohshimo S, Griese M, Guzman J, Costabel U.

Respirology. 2017 Oct;22(7):1371-1378. doi: 10.1111/resp.13082. Epub 2017 May 31.

16.

[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017].

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2017 Jul;71(7):460-474. doi: 10.1055/s-0043-106160. Epub 2017 May 30. German. Erratum in: Pneumologie. 2017 Jul;71(7):474.

PMID:
28558396
17.

Reply: Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Costabel U, Stansen W, Stowasser S.

Am J Respir Crit Care Med. 2017 May 1;195(9):1275. doi: 10.1164/rccm.201610-2155LE. No abstract available.

PMID:
28459331
18.

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.

Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler KU, Costabel U.

Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12.

19.

Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications.

Ravaglia C, Wells AU, Tomassetti S, Dubini A, Cavazza A, Piciucchi S, Sverzellati N, Gurioli C, Gurioli C, Costabel U, Tantalocco P, Ryu JH, Chilosi M, Poletti V.

Respiration. 2017;93(4):285-292. doi: 10.1159/000456671. Epub 2017 Mar 1.

20.

FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis.

Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Shime N, Bonella F, Guzman J, Costabel U, Kohno N.

Respir Med. 2017 Feb;123:105-109. doi: 10.1016/j.rmed.2016.12.007. Epub 2016 Dec 22.

PMID:
28137485

Supplemental Content

Loading ...
Support Center